

### **In the Claims**

1.- 13. (Cancelled)

14. (Currently Amended) A pharmaceutical composition, comprising an antigen presenting cell pulsed with an inactivated non-recombinant human immunodeficiency virus (HIV), wherein the composition expands expression of virus-specific CD8+T cells.

15.-32. (Cancelled)

33. (Currently Amended) The pharmaceutical composition of Claim 14, wherein said antigen-presenting cell is a dendritic cell.

34. (Currently Amended) The pharmaceutical composition of Claim 33, wherein said dendritic cell is an autologous dendritic cell.

35. (Currently Amended) The pharmaceutical composition of Claim 33, wherein the dendritic cell is a monocyte-derived dendritic cell.

36. (Currently Amended) The pharmaceutical composition of Claim 14, wherein the inactivated human immunodeficiency virus is chemically inactivated.

37. (Currently Amended) The pharmaceutical composition of Claim 14, wherein the inactivated human immunodeficiency virus is inactivated by 2,2'-dithiopyridine or aldrithiol-2.

38. (Currently Amended) The pharmaceutical composition of Claim 14, wherein the inactivated human immunodeficiency virus is non-thermally inactivated.

39. (Currently Amended) The pharmaceutical composition of Claim 36, wherein the inactivated human immunodeficiency virus is an autologous human immunodeficiency virus.

40. (Currently Amended) The pharmaceutical composition of Claim 38, wherein the inactivated human immunodeficiency virus is an autologous human immunodeficiency virus.
41. (New) The pharmaceutical composition of Claim 38, wherein said virus-specific CD8+ cells kill HIV-infected cells.
42. (New) The pharmaceutical composition of Claim 14, wherein said inactivated human immunodeficiency virus is an inactivated autologous human immunodeficiency virus.
43. (New) A pharmaceutical composition comprising:  
a therapeutically effective amount of an antigen presenting cell pulsed with an inactivated non-recombinant human immunodeficiency virus (HIV); and  
a pharmaceutically acceptable carrier;  
wherein the composition expands expression of virus-specific CD8+T cells.
44. (New) The pharmaceutical composition of Claim 43, wherein said inactivated human immunodeficiency virus is an inactivated autologous human immunodeficiency virus.
45. (New) The pharmaceutical composition of Claim 43, wherein said antigen-presenting cell is a dendritic cell.
46. (New) The pharmaceutical composition of Claim 45, wherein said dendritic cell is an autologous dendritic cell.
47. (New) The pharmaceutical composition of Claim 45, wherein the dendritic cell is a monocyte-derived dendritic cell.
48. (New) The pharmaceutical composition of Claim 43, wherein the inactivated human immunodeficiency virus is chemically inactivated.

49. (New) The pharmaceutical composition of Claim 43, wherein the inactivated human immunodeficiency virus is inactivated by 2,2'-dithiopyridine or aldrithiol-2.

50. (New) The pharmaceutical composition of Claim 43, wherein the inactivated human immunodeficiency virus is non-thermally inactivated.

51. (New) The pharmaceutical composition of Claim 48, wherein the inactivated human immunodeficiency virus is an autologous human immunodeficiency virus.